Condition: Hepatocellular Carcinoma · Sponsor: Fujian Provincial Hospital
This is a multicenter, Single-arm, Real-world Study to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combined with Tislelizumab (Triple Therapy) for patients with Hepatocellular Carcinoma (HCC) with bile duct tumor thrombus (BDTT).
This description comes directly from the study's public registry record.
Mao-Lin Yan · 0591-88217140 · yanmaolin74@163.com
Always discuss trial participation with your own doctor first.
| First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Not Yet Recruiting |
| Mengchao Hepatobiliary Hospital of Fujian Medical University | Fuzhou, Fujian, China | Not Yet Recruiting |
| Fujian Provincial Hospital | Fuzhou, Fujian, China | Recruiting |
| Zhongshan Hospital of Xiamen University | Xiamen, Fujian, China | Not Yet Recruiting |
| First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Not Yet Recruiting |
| Zhangzhou Affiliated Hospital of Fujian Medical University | Zhangzhou, Fujian, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06602011